Neko Health has completed a $700 million Series C round as the Stockholm-based health technology company prepares to enter the US market in 2026.
The round was led by Lightspeed Venture Partners and co-led by O.G. Venture Partners, with participation from existing investors Atomico, General Catalyst and Lakestar, as well as new backers including Liberty City Ventures, Positive Sum and BDT & MSD. Neko Health said David Ofer of O.G. Venture Partners will join its board, subject to regulatory approval.
The company said it will use the new funding to launch in the US, scale its preventive healthcare model, and invest further in research and technology. Its first US clinics are planned for New York and other cities in 2026.
Founded in Stockholm, Neko Health offers a 60-minute, non-invasive and radiation-free health assessment that combines proprietary sensors, blood analysis and an in-person consultation with a medical professional. The company builds its hardware, software and consumer experience in-house as it expands its preventive care platform.
The round was led by Lightspeed Venture Partners and co-led by O.G. Venture Partners, with participation from existing investors Atomico, General Catalyst and Lakestar, as well as new backers including Liberty City Ventures, Positive Sum and BDT & MSD. Neko Health said David Ofer of O.G. Venture Partners will join its board, subject to regulatory approval.
The company said it will use the new funding to launch in the US, scale its preventive healthcare model, and invest further in research and technology. Its first US clinics are planned for New York and other cities in 2026.
Founded in Stockholm, Neko Health offers a 60-minute, non-invasive and radiation-free health assessment that combines proprietary sensors, blood analysis and an in-person consultation with a medical professional. The company builds its hardware, software and consumer experience in-house as it expands its preventive care platform.